SCWorx Corp. (NASDAQ: WORX) is expected to list on 2026-10-07, but the price range has not been disclosed. This is a resale registration, not a traditional primary IPO, so the company will not receive proceeds from the share sales. Watch whether investors focus on the software story or the going-concern and dilution overhang.
SCWorx Corp. (NASDAQ: WORX) is expected to list on 2026-10-07, but the price range has not been disclosed. This is a resale registration, not a traditional primary IPO, so the company will not receive proceeds from the share sales. Watch whether investors focus on the software story or the going-concern and dilution overhang.
Quick Facts
Expected listing date: October 7, 2026
Exchange: NASDAQ
Proposed symbol: WORX
Status: Expected
Company Overview
SCWorx Corp. provides software and data services for healthcare providers, with a focus on data normalization, interoperability, and analytics across supply chain, financial, and clinical systems. The company says its software is delivered as a SaaS product hosted in AWS or RackSpace and sold under fixed-term contracts, typically one to five years. Its principal executive offices are in Tampa, Florida.
The business sits in healthcare provider IT, where buyers want cleaner data, better workflow integration, and lower administrative friction. SCWorx frames its market around healthcare digitization, interoperability needs, and supply-chain efficiency, but it also competes in a crowded field where manual processes, larger software vendors, and point solutions all vie for the same budget dollars. The company does not disclose a formal TAM in the filings reviewed, so the market opportunity has to be judged from the use case rather than a top-down size claim.
Why They're Going Public
This filing is not a primary capital raise. It is a resale registration statement for existing shareholders and warrant holders, and SCWorx says it will not receive proceeds from the sale of those shares. That makes the listing more about creating liquidity for insiders and warrant-related holders than funding a new growth plan.
The only direct cash benefit to SCWorx would come from warrant exercises, which the company says could generate up to approximately $16.5 million depending on exercise mechanics. If that cash comes in, management says it would be used for working capital and general corporate purposes. For shareholders, the key question is whether the listing improves market visibility and trading liquidity enough to offset the fact that the company itself is not being recapitalized by the share sale.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
SCWorx remains a small-revenue business with uneven top-line performance. Revenue was $2,989,599 in 2024 versus $3,804,943 in 2023, a decline of about 21%. For the first nine months of 2025, revenue was $2,108,730 compared with $2,313,850 in the same period of 2024, showing continued pressure rather than a clear acceleration.
Profitability has improved from a loss-reduction standpoint, but the company is still losing money. Net loss was $1,136,225 in 2024 versus $3,981,144 in 2023, while the net loss for 9M 2025 widened to $3,694,927. Gross profit in 9M 2025 was $569,207 on revenue of $2,108,730, implying a gross margin of roughly 27%, versus about 25% in 9M 2024. Cash on hand was approximately $684,000 at Sept. 30, 2025, and the company used $1,414,534 in cash from operations in the first nine months of 2025, so liquidity remains tight.
Risk Factors
The biggest risk is that SCWorx is still operating with recurring losses and negative operating cash flow. The company has explicitly raised going-concern concerns in its filings, and the cash balance of roughly $684,000 at Sept. 30, 2025 leaves little room for error if collections slow or operating costs rise. That makes the path to self-funding especially important.
Customer concentration is another major issue. SCWorx says its customer base is highly concentrated, with one or a few customers representing a substantial portion of revenue and gross profit, so the loss of a major account could materially hurt results. The company also faces Nasdaq listing risk tied to a minimum bid price deficiency, plus competition, healthcare regulation, rapid technology change, and potential dilution from future financing or warrant exercises. Because this is a resale registration rather than a standard IPO, there is also no traditional lockup structure to absorb supply in the way investors often expect from a new listing.
Comparable Public Companies
The closest public comps are healthcare IT and workflow software names such as Computer Programs and Systems (CPSI), Evolent Health (EVH), and Health Catalyst (HCAT). A broader peer set could also include R1 RCM (RCM) and Phreesia (PHR), though those businesses are not direct matches for SCWorx’s smaller scale and narrower supply-chain/data-management focus. Relative to those names, SCWorx is much smaller, less profitable, and more dependent on a concentrated customer base.
The comp group gives a mixed read on the sector. Larger healthcare software and services names generally trade on revenue quality, recurring contracts, and margin durability, while smaller or loss-making names tend to be valued more cautiously. In broad terms, the group has not been a uniform momentum trade over the last 6 to 12 months; investors have favored companies with clearer growth and cash flow, while lower-scale, higher-risk stories have faced more selective demand. That backdrop matters here because SCWorx is coming to market with modest revenue, negative cash flow, and no disclosed pricing yet.
Verdict
What to watch as SCWorx prices is not just the headline listing date, but whether investors are willing to look through the resale structure and focus on the operating story. The company is not raising primary proceeds from the share sale, revenue is still below $3 million annually, and cash remains limited. That means the setup will likely hinge on whether the market believes the software platform can stabilize revenue and reduce dependence on a small number of customers.
The timing angle is straightforward: this is a small healthcare software listing coming during a period when investors are selective on unprofitable microcaps and especially cautious on names with dilution and listing-risk overhangs. The narrative is not a classic growth IPO; it is a liquidity event wrapped around a turnaround-style operating profile. Shareholders should watch the final pricing, any warrant-exercise economics, and whether the market treats the deal as a tradable healthcare tech story or as a supply-heavy resale listing with limited fundamental support.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
